Flow cytometry in Chronic Myeloid Neoplasms: Current Recommendations and Challenges

The role of flow cytometric immunophenotyping (FCIP) in the diagnosis and follow up of lymphoproliferative disorders, plasma cell neoplasms and acute leukemias is well established. However, its value in chronic myeloid neoplasms remains debatable. Systemic mastocytosis, and more recently chronic myelomonocytic leukemia, are the only two groups for which immunophenotypic characterization is incorporated into the diagnostic criteria. Over the past two decades, several studies have demonstrated a value for FCIP in the diagnosis of myelodysplastic neoplasms (MDS). Recent guidelines recommend the integration of FCIP data with other modalities in the work-up of MDS. Strategies and challenges in FCIP analysis of MDS will be discussed. The value of deep immunophenotypic analysis of the blast population will also be explored.
After viewing this lecture, participants should be able to:
1. Discuss the role of flow cytometric immunophenotyping in the work-up of chronic myeloid neoplasms.
2. Current recommendations on the application of flow cytometry in the diagnosis of myelodysplastic syndromes.
3. Describe strategies and challenges in the flow cytometric evaluation of myelodysplastic syndromes
Afshin Shameli, MD, PhD
Division of Hematopathology, Department of Laboratory Medicine and Pathology, University of Washington
05/17/23

[@Hemepath]

Great lecture! Thank you! It is very helpful.